Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.
CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.
Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.
Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.
Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.
The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.
Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.
Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.
An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.
Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.
David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.
